15 Sep

GoodGut to participate in Biospain 2016 in Bilbao

GoodGut to participate in Biospain 2016 in Bilbao

634x194-banner-biospain-2016

Forging bonds with future industrial partners for the innovative non-invasive system for early detection of colorectal cancer (RAID-CRC) is the goal GoodGut has set for their time at Biospain 2016, as well as at other events in the sector over the coming months.

Biospain, which will be held from 28 to 30 September in Bilbao by the Spanish Association of Biotech Companies (Asebio), has become the meeting point for biotechnology firms in Spain, attracting more than 850 companies and investors from 37 countries.

Clinical study begins at five hospitals in Catalonia

RAID-CRC has recently received funding through the Ministry of the Economy and Competitiveness 2016 ‘Retos’ programme. It will also begin clinical validation this September with 500 patients at the Dr. Josep Trueta University Hospital, Bellvitge University Hospital, Catalan Institute of Oncology, Vic University Hospital and Santa Caterina Hospital in Girona. “We will analyse different risk groups and that will allow us to better establish who the product targets,” explains Mariona Serra, CEO of GoodGut. The company has also begun the national phase of PCT (Patent Cooperation Treaty).

The current screening method is the faecal occult blood test (FOB), but it isn’t as effective as it is less specific and doesn’t detect pre-symptomatic CRC adenomas. The new system being developed by GoodGut is based on bacterial markers in faeces and will allow doctors to pre-diagnose colon cancer and determine risk levels in the early stages.

Schedule a meeting and we’ll tell you all about our product (partneringONE®)

26 Jul

GoodGut gets €175,000 CDTI Neotec grant

GoodGut gets €175,000 CDTI Neotec grant

parccientificgirona_web

Just days after the good news that the Ministry of the Economy and Competitiveness had granted GoodGut €1.1 million under the 2016 Retos programme, the company found out that it will also receive support from the 2015 CDTI Neotec grants: €175,000.

In this case, the funding will not go to developing a specific project but be used to consolidate the company’s research lines and its laboratory located at the University of Girona Science and Technology Park.

The Neotec grants are among the most competitive in the science/business arena in Spain. More than 500 SMEs participated in this call for proposals. The aspects that the CDTI gives the most weight are that the business strategy be based on technological development, as a competitive factor to set the company apart, and that it has its own lines of R&D.

19 Jul

Girona Regional Council supports GoodGut innovation

Girona Regional Council supports GoodGut innovation

diputaciogirona_goodgut_web_v2

GoodGut is one of 14 companies that have been selected under the Girona Regional Council business support program, which will create some 40 jobs throughout the province this year.

“We want to encourage the hiring of new personnel and drive actions to improve issues associated with innovation and technology within companies,” highlighted Josep Antoni Frias, regional councillor for Economic Promotion and DIPLAB in the Girona Regional Council. Frias met with representatives of the companies receiving this support on 28 July. CEO Mariona Serra attended on behalf of GoodGut.

The Regional Council valued the cutting-edge research being carried out at Goodgut in the field of digestive diseases, as well as the team’s history. This biotechnology firm was created in 2014 by Dr. Xavier Aldeguer, head of Digestive Medicine at Hospital Josep Trueta; Dr. Jesús García-Gil, Microbiology Chair; and Mariona Serra, PhD in pharmacology.  Afterwards, the team was joined by Jaume Amat as a strategic consultant through the Bioemprèn programme (he is also on the CataloniaBio Board of Directors). Goodgut currently has a team of five working at its facilities in the University of Girona Science and Technology Park – Girona Emprèn.

Photo: Martí Artalejo

12 Jul

GoodGut gets Retos grant for non-invasive test for early detection of colon cancer

GoodGut gets Retos grant for non-invasive test for early detection of colon cancer

goodgut_equip

Ministry of the Economy and Competitiveness has given GoodGut €1.1 million under the Research Challenges (Retos) programme to validate and develop a non-invasive system for colorectal cancer screening based on bacterial markers in faeces. The project is called Risk Assessment Intestinal Disease for Colorectal Cancer (RAID-CRC) and will last three years.

The innovation of this new test lies in its ability to detect precancerous lesions in patients from a stool sample even before they experience symptoms. This will “reduce the number of false positives you get with the faecal occult blood test, decrease the need for colonoscopies and help prevent colorectal cancer,” explains Dr Mariona Serra, co-founder and CEO of GoodGut. RAID-CRC will be implemented to screen people with mid-to-high risk, meaning individuals over 50.

The test is currently undergoing clinical validation, which will finish over the coming months, at the Digestive System Unit at Dr. Josep Trueta University Hospital, led by Dr. Xavier Aldeguer; the Digestive System Unit at Bellvitge University Hospital, led by Dr. Jordi Guardiola; and the Genetic Counselling Unit at the Catalan Institute of Oncology, led by Dr. Gabriel Capellà and Dr. Joan Brunet.

Close collaboration between public institutions and companies is key to the development of medical devices like RAID-CRC. “The ‘Retos’ programme makes this interdisciplinary action possible, ensuring the success of the project,” says Mariona Serra.